Proliferation Potentials of Human Intracranial Neoplasms Assessed with Ki-67 (MIB-1) Labeling Index and Argyrophilic Nucleolar Organizer Regions by Tokunaga Yoshiharu et al.
Acta Med. Nagasaki 42 : 44-50
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 To evaluate the accuracy of the Ki-67 labeling index (LI) as 
an index of brain tumor proliferation, specimens of 303 
intracranial neoplasms were examined for tumor prolifera-
tion potentials as assessed by MIB-1 (Ki-67 antigen) im-
munostaining and/or counting the argyrophilic nucleolar 
organizer regions (Ag-NORs). The Ki-67 LIs were higher in 
the histologically high grade tumors, i.e., the metastatic 
carcinomas, malignant lymphomas, glioblastomas, medul-
loblastomas, anaplastic astrocytomas, anaplastic oligo-
dendrogliomas, anaplastic ependymomas, and anaplastic 
meningiomas compared to the histologically low grade 
tumors, i.e., the pilocytic astrocytomas, grade II astro-
cytomas, oligodendrogliomas, ependymomas, meningio-
mas other than those of the anaplastic variety, and pituitary 
adenomas. The number of Ag-NORs was not correlated with 
the tumor grade, and was inconsistent with the growth 
potential in some tumors. Moreover, in the consecutive 
sections of 87 tumors stained for both Ki-67 and Ag-NORs, 
the number of Ag-NORs did not correlate with the tumor 
Ki-67 LI in a regression analysis (r = 0.139). The patients 
with a high grade astrocytoma (anaplastic astrocytoma and 
glioblastoma) and a tumor Ki-67 LI > 10 had significantly 
shorter survival periods than those of the patients with a 
Ki-67 LI < 10 (p = 0.029). Our results thus suggest that Ki-67 
is a potential marker of tumor growth activity and that the 
Ki-67 LI may be of use as an indicator of the prognosis of 
patients with brain tumor. The number of Ag-NORs may not 
always reflect the growth potential of some tumors.
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Introduction 
 Neoplastic diseases are characterized by un-coordinated 
cell growth. Cellular proliferation follows an orderly 
progression through the cell cycle, which is governed by 
many protein complexes. The growth of brain tumors 
results from the relative proportion of cells contained in 
three populations : a) cycling/proliferative ; b) quiescent 
(G0)/static, and c) terminally differentiated/dying. 
Intracranial neoplasms are critical due to their growth
rate, origin and location, which directly reflect the surgi-
cal outcome, and a proportion of these tumors recurs even 
after complete surgical resection. The growth rate directly 
affects the patient's prognosis. Thus, quantification of the 
proliferative potential would help to predict the biological 
behavior of these tumors and may influence their treat-
ment. Among the cell proliferation markers, BUdR is an 
experimental agent which estimates the S-phase fraction 
of cells. Its identification requires the pretreatment of 
living cells'). Proliferating cell nuclear antigen (PCNA) is 
a 36-kDa DNA polymerase-delta auxiliary protein which 
accumulates in the nucleus during the S phase of the cell 
cycle'). Labeling with the monoclonal antibody Ki-67 
recognizes the native Ki-67 antigen and recombinant 
fragments of the Ki-67 molecules expressed in the G1, S, 
G2, and M phases of the cell cycle but absent in the 
quiescent cells'), The antibody to Ki-67 has been used 
extensively in recent years both as a laboratory index and 
as a clinical index of tumor proliferation'."). In addition, 
the number of argyrophilic nucleolar organizer regions 
(Ag-NORs) has been reported to correlate closely with 
cellular proliferations13-16). The present study was under-
taken to evaluate the accuracy of the Ki-67 LI by using 
MIB-1 immunostaining and the number of Ag-NORs as 
indicators of brain tumor proliferation, with a special 
emphasis on astrocytic tumors which constitute 50% of all 
brain tumors.
Materials and Methods 
 Specimens of 303 brain tumors obtained from patients 
who had undergone surgical resection at our Department 
of Neurosurgery, Nagasaki University School of Medicine, 
Nagasaki, Japan, were retrospectively analyzed for the 
proliferative nuclear Ki-67 antigen and Ag-NOR. All of the 
tumors samples had been formalin-fixed and paraffin-
embedded. The 5-,um tumor sections were cut and stained 
with hematoxylin and eosin for histologic classification 
and grading according to the World Health Organization
Table 1. Ki-67 labeling index ( LI) in intracranial neoplasms.
                 Histology Ki-67 LI* Ag-NOR/cell* 
          Pilocytic astrocytomas 1.20±1.56 (9) ND 
         Astrocytomas (gradeII) 1.52±3.18 (32) 2.04±0.54 (8) 
          Anaplastic astrocytomas 13.47±11.40 (34) 2.40±0.77 (7)
         Glioblastomas 19.54±18.34 (59) 2.71±1.13 (24) 
         Oligodendrogliomas 2.95±3.89 (6) 1.91 (2) 
         Anaplastic oligodendrogliomas 13.08±3.47 (3) 1.92±0.99 (6) 
          Oligoastrocytomas 4.85 (2) ND 
         Ependymomas 1.67±2.89 (3) 2.30 (2) 
         Anaplastic ependymomas 28.64(2) 2.97 (2) 
         Medulloblastomas 12.31±10.78 (11) 2.99±1.49(19) 
          Meningiomas 
             Meningotheliomatous 2.68±4.74 (13) 2.03±0.48 (29) 
             Fibrous 1.19±1.97 (8) 1.98±0.54 (26) 
             Transitional 1.27±1.79 (8) 1.94±0.66 (20) 
             Anaplastic 16.76 (2) 3.53±1.78 (4) 
             Angiomatous 1.33±2.31 (3) 1.63±0.41 (3) 
          Pituitary adenomas 1.52±4.03 (17) 2.09±0.49 (29) 
         Metastatic brain tumors 37.69±21.37 (14) 2.99±1.49 (19) 
         Malignant lymphomas 36.78±38.64 (4) 2.27 (2) 
* , mean±standard deviations. The numbers of tumors examined by each method are in parentheses. ND : notdone
Histological Classification of Central Nervous System 
Tumors"). Consecutive tumor sections were stained for the 
Ki-67 antigen and Ag-NOR. The brain tumors are detailed 
shown in Table 1. 
Immunohistochemical staining of Ki-67 antigen 
 The staining method used was that which we described 
previously'). Deparaffinized tissue sections were rinsed in 
distilled water for rehydration, placed in a glass container 
filled with 10 mM citrate buffer (pH 6.0), processed in a 
domestic micro-oven (Hitachi MR-A330, Tokyo, Japan) 
for 15 minutes at 500 W, and then cooled to room tempera-
ture. After pretreatment of the sections with 0.2% trypsin 
followed by a rinse in phosphate-buffered saline (PBS), the 
tissue endogenous peroxidase activity was blocked with 
0.3% hydrogen peroxide in methanol for 30 minutes. The 
sections were then incubated with the monoclonal mouse 
anti MIB-1 "paraffin Ki-67" antibody (Immunotech S. A., 
Marseille, Cedex, France) diluted 1 : 50 in PBS, and 
incubated overnight at 41C. The bridge antibody applied 
was biotinylated goat anti-mouse immunoglobulin (1 : 100 
in PBS), at room temperature for 1 hr, and then the avidin 
biotin complex (Vector Laboratories, Burlingame, CA) 
was applied for 45 minutes. After each antibody incuba-
tion, the sections were washed three times for 5 minutes 
each time in PBS. The substrate chromogen was DAB. The 
sections were counterstained in Mayer's hematoxylin, 
dehydrated, and mounted. The Ki-67-positive cells were 
counted from the areas of a given tumor section where the 
maximum numbers of tumor cells were immunostained. In 
each section, all of the tumor cells (immunopositive and 
negative) of five to ten (varied for available tumor cells)
such light microscopic high-power fields set with a video 
monitoring screen were counted. The Ki-67 labeling index 
(LI) of the immunopositive cells was obtained as the 
percentage of the total number of tumor cells in the 
visualized fields of that section. 
Staining of Ag-NORs 
 After tissue sections were deparaffinized, they were 
stained according to the method described by Shibuya et a 
110'. Briefly, tissue sections were covered with a solution 
consisting of 2 % gelatin in 1 % aqueous formic acid mixed 
with 50 % aqueous silver nitrate solution (1 : 2 v/v) for 30 
minutes in a dark place. The sections were then rinsed 
briefly in distilled water and dehydrated in graded 
alcohols, cleared in zyline and finally mounted. All tumor 
cells in the maximum cellular areas of the visualized 
microscopic high-power fields were randomly counted 
irrespective of the presence or absence of Ag-NORs as 
black dots. A total of 200 cells were counted, and the 
average number of Ag-NORs per cell was obtained. 
Patient Survival and statistical analysis 
 Our analysis of patient survival was restricted to the 
patients with astrocytic tumors who did not have a tumor 
recurrence. All of the patients with astrocytic tumors had 
been followed-up for at least for six months at the time of 
the preparation of this present manuscript. The maximum 
follow-up period for the patients with astrocytomas was 
13 years. The Ki-67 LI of the astrocytic tumors was 
analyzed in relation to the survival of patients. The mean 
values and standard deviations (SD) for the Ki-67 LI,
Ag-NOR count and survival time were calculated, and the 
p-values were obtained using Student's t-test (Ki-67), 
regression analysis, or the log rank test (survival).
Results 
Ki-67 labeling index in the intracranial neoplasms 
 The staining pattern of the Ki-67 antigen is shown in 
Fig. 1. The distributions of Ki-67 antigen-immunopositive 
cells were either diffusely or focally distributed. The Ki-67 
LIs (mean±SD) of the various brain tumors are shown in 
Table 1. In general, the histologically high grade tumors 
showed higher Ki-67 LIs. Among the astrocytic brain 
tumors, the mean Ki-67 LI was 1.2 ± 1.56 in the pilocytic
astrocytomas, 1.52:L3.18 in the grade II astrocytomas, 
13.47±11.40 in the anaplastic astrocytomas, and 19.54± 
18.34 in the glioblastomas. The anaplastic astrocyomas 
and glioblastomas had significantly higher Ki-67 LIs 
compared to the histologically low grade (pilocytic, grade 
I and fibrilary/protoplasmic, grade II) astrocytomas (p< 
0.0001). Among the oligodendroglial tumors, the mean 
Ki-67 LI was 2.95 ± 3.89 in the pure oligodendrogliomas, 
13.08±3.47 in the anaplastic oligodendrogliomas, and 4.85 
in the two mixed oligoastrocytomas. The Ki-67 LI in the 
benign ependymomas was 1.67 ± 2.89, whereas in the 
anaplastic ependymomas it was 28.64. In the meningeal 
tumors, the mean Ki-67 LI in the meningotheliomatous 
meningiomas was 2.68 ± 4.74 ; in the fibroblastic men-
ingiomas, 1.29 ± 1.97; in the transitional meningiomas, 
1.27±1.79 ; in the angiomatous meningiomas, 1.33 ± 2.31;
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Fig. 1. The Ki-67 immunoreactivity in intracranial neoplasms stained with MIB-1 antibody (avidin biotin complex method) 
showed many Ki-67-immunopositive cells in glioblastomas (a), anaplastic meningiomas (b), and metastatic brain tumors (c), 
and few Ki-67-positive cells in meningotheliomatous meningiomas (d).
Fig. 2a Fig. 2b
Fig. 2. Ag-NOR staining in a pituitary adenoma (a) and in a metastatic brain tumor (b). Ag-NORs are seen as black dots in 
the nucleus.
Fig. 3. The correlation between Ki-67 LI and Ag-NOR in the 
consecutive sections of 87 brain tumors stained for both Ki-67 
(MIB-1 antibody) and Ag-NOR. A linear regression analysis 
showed no significant correlation (r = 0.139).
and in the anaplastic meningiomas, 16.76. The mean Ki-67 
LI in the medulloblastomas was 12.31 ; in the pituitary 
adenomas, 1.52 ± 4.03 ; and in the metastatic brain tu-
mors, 37.69±21.37. 
Ag-NORs in the ntracranial neoplasms 
 The staining pattern of Ag-NORs is shown in Fig. 2. The 
mean (±SD) numbers of Ag-NORs per cell in the various 
tumors are shown in Table 1. Among the astrocytic brain
tumors, the mean number of Ag-NORs per cell was 
2.04±0.54 in the grade II astrocytomas, 2.40±0.77 in the 
anaplastic astrocytomas, and 2.71 ± 1.13 in the glio-
blastomas. This values were not significantly different. 
The mean number of Ag-NORs per cell in the benign 
oligodendrogliomas (2 cases) was 1.91, whereas in the 
anaplastic oligodendrogliomas (6 cases), the value was 
1.92±0.99. The mean Ag-NOR numbers in the benign 
ependymomas and anaplastic ependymomas were 2.30 and 
2.97, respectively. Among the meningiomas, although a 
higher Ag-NOR number was noted in the anaplastic 
meningiomas (4 cases, mean 3.53 per cell), this value was 
not significantly different compared to the value obtained 
for the benign meningiomas. In the pituitary adenomas, 
the mean Ag-NOR number was 2.09±0.49, in the met-
astatic brain tumors it was 2.99±1.49, and in the malig-
nant lymphomas (2 cases), it was 2.27. Thus, the number 
of Ag-NORs was not consistent with the growth potential 
of some tumors. Consecutive sections of 87 brain tumors 
were stained for tboth he Ki-67 antigen and Ag-NOR, and 
the correlation between the two proliferation index values 
was obtained by regression analysis. No correlation was 
obtained between the Ki-67 LI and Ag-NOR values in these 
tumor sections (r = 0.139), as shown in Fig. 3. 
Ki-67 LI and survival of patients with astrocytic tumors 
 Ninety-five percent of the patients with pilocytic or 
grade II astrocytomas were still alive, when this study was 
performed. The survival periods of only the patients with 
anaplastic astrocytomas or glioblastomas were analyzed 
in relation to the tumor Ki-67 LIs. Among the anaplastic 
astrocytoma-patients with a mean Ki-67 LI< 10, the 
survival time was 499.14 ± 334.89 days ; among such 
patients with a Ki-67 LI > 10, the survival time was
278.1±149.55 days (p = 0.051, log rank test). The same 
Ki-67 LI cut-off values were applied to the patients with 
glioblastomas, and the survival times were 416.15±300.32 
and 216.65±110.88 days, respectively (p = 0.038, log rank 
test). Again, with the above Ki-67 LI cut-off values, the 
patients with combined high grade astrocytomas (anaplas-
tic astrocytomas and glioblastomas) with a Ki-67 LI < 10 
had significantly shorter survivals (p = 0.029). The 
Kaplan-Meier curves for patient survival are shown in 
Fig.4.
Fig. 4. The Kaplan-Meier curves for the patient groups 
defined by the tumor MIB-1 Ki-67 LI < 10 (bold line) and > 10 
(plain line). (A) patients with high grade astrocytomas (p = 
0.039, log rank), (B) patients with anaplastic astrocytomas 
(p = 0. 051, log rank), and (C) patients with glioblastomas 
(p = 0.031, log rank).
Discussion 
 In the present study we used two markers to assess the 
proliferative potential of various brain tumors i.e., the 
Ki-67 LI (MIB-1) and the number of Ag-NORs. The previ-
ously available antibody to Ki-67 could be applied only to 
frozen tissue sections ; the present antibody used here to 
detect Ki-67, MIB-1, can effectively be applied to paraffin-
embedded tissue sections, and MIB-1 immunostaining has 
been reported to be superior to that of Ki-67 in individual 
tumors'). In the present series, the malignant lymphomas, 
glioblastomas, medulloblastomas, and tumors meta-
stasized to the brain,t which represent the most malignant 
form of brain tumors in terms of histology and prognosis, 
had higher Ki-67 LIs compared to the schwannomas, 
pituitary adenomas, pilocytic astrocytomas, astro-
cytomas, pure oligodendrogliomas, pure ependymomas, 
and benign meningiomas. The histologically anaplastic 
groups of tumors, i.e., the anaplastic astrocytomas, 
anaplastic oligodendrogliomas, anaplastic ependymomas, 
and anaplastic meningiomas also had higher Ki-67 LIs than 
their benign counterparts. The relationship between the 
Ki-67 LI and the histological grade of brain tumors has 
been investigated in many laboratories"',"'); however, the 
range of LI within histological grades varied widely. In 
almost all of those studies, the authors used a microwave 
oven for the antigen unmasking of paraffin-embedded 
tissues before MIB-1 immunostaining. We have always 
used a domestic micro-oven for tissue processing') and the 
Ki-67 LIs of the tumors obtained in the present study were 
in no way inferior to those robtained with the use of a 
microwave oven"). The Ki-67 LIs we observed in different 
tumors are in agreement with those of the previous 
reports, in which the authors also used the same MIB-1 
antibody to detect Ki-67 antigen in paraffin-embedded 
tissue sections. 
  Astrocytomas are the most common primary gliomas, 
with the highly anaplastic glioblastomas being the most 
frequently occurring astrocytic tumors. Distinctive histo-
logical features permit astrocytic tumors to be graded into 
levels of anaplasia, and these histological grades correlate 
with the biological behavior of the tumor and patient 
prognosis. However, there is also a strong correlation
among the patient age, tumor grade, and prognosis. More 
objective indicators of tumor proliferative potential, such 
as BUdR or Ki-67, are currently being investigated with 
the hope that these will be a more accurate means of 
predicting patient survival. In the present study, we found 
that the anaplastic astrocytomas and glioblastomas had 
significantly higher Ki-67 LIs compared to the pilocytic 
astrocytomas and grade II astrocytomas. The distribution 
of Ki-67 LI values for the anaplastic astrocytomas and 
glioblastomas overlapped to the extent that these two 
grades were mostly indistinguishable by the Ki-67 LI in 
individual tumors, although the mean Ki-67 LI of the 
glioblastomas was high, as previously reported by other 
authors"',"'. Survival analyses of high grade glioma 
patients did not identify significantly different subgroups 
with respect to the Ki-67 LI (9 and present study). In this 
respect, proliferation indices appear to be a less significant 
prognostic variable within the group of high grade lesions 
than are other features used in the morphological assess-
ment of these lesions, such as the presence of necrosis or 
vascular proliferation. We found that in the group of 
glioblastoma patients, the survival time decreased as the 
tumor Ki-67 LI increased. Other authors have also ana-
lyzed the survival time of patients with high grade 
astrocytomas (glioblastoma or anaplastic astrocytomas) 
in respect to tumor Ki-67 LIs with different cut-off 
points'-'9). The mean Ki-67 LIs for anaplastic astrocytomas 
(14.3) and glioblastomas (18.9) reported by Montine 
et al'). were in the same range as those we obtained for 
these two tumor subclasses. Using the Ki-67 LI cut-off 
values of <7.5 and>7.5, Montine et al. suggested that the 
LI<7.5 result indicated a long-term survivor within the 
high grade glioma group ; however, it did so with low 
specificity. One recent study') included a survival analysis 
of glioma patients using the Ki-67 LI and PCNA as the 
prediction values, and the authors suggested that the 
survival time was significantly reduced when either the 
Ki-67 LI or PCNA LI was increased. In that study, the 
Ki-67 LI cut off values were LI<5 and ?5. In th epresent 
study, we divided anaplastic astrocytomas and glioblasto-
mas into two groups according to their Ki-67 LI (<10 
and >10), and we demonstrated that patients with a 
tumor Ki-67 LI >10 survived for a significantly shorter 
time than the patients with a tumor Ki-67 LI < 10. 
Specifically, we showed a significant correlation of the 
Ki-67 LI and the survival of the glioblastoma patients 
using the above Ki-67 LI cut-off values. Although the 
survival periods of the patients with anaplastic 
astrocytomas with a Ki-67 LI <10 were longer, the differ-
ence was not significant. This may be due to differences in 
the number of tumors in each group, wide standard 
deviations, the Ki-67 LI cut-off values used, and other 
factors related to tumor prognosis. Another study') 
suggested that the Ki-67 LI has in general the best sensitiv-
ity and specificity in placing patients correctly in groups
of survivors and non-survivors. Our ersults support this 
hypothesis. 
 Other proliferative indices also correlate to the tumor 
proliferation activity and tumor histological gradesi°•1L19.20' 
In brain tumors, a good correlation between the Ki-67 LI 
and the LI of S-phase-labelled PCNA and BUdR has been 
reported",",'). The labeling index of DNA polymerase alpha 
sometimes showed higher values than the Ki-67 LI in brain 
tumors"). Another study compared the thalium TI-201 
single photon emission computed tomography (SPECT)-
imaging findings of brain tumors and their Ki-67 LI ; the 
radionucleotide uptake of TI-201 in the tumor specimens 
was high in the tumors with a high Ki-67 LI22'. NORs are 
loops of DNA that contain the RNA gene and are tran-
scribed by RNA polymerase ?'. These regions are impor-
tant in the regulation of protein synthesis) and can be 
identified easily by the argyrophilic technique. Some 
studies have shown a close correlation between the Ag-
NOR number with cell proliferation and the clinical 
behavior of the tumors"'', while other studies did not'). In 
the present study, although some of the high grade tumors 
had somewhat higher Ag-NOR numbers than the low grade 
tumors, the overall difference was not significant. We 
found that the pituitary adenoma, a benign tumor that 
rarely recurs or shows malignant transformation, had a 
mean Ag-NOR number greater than those of the 
astrocytomas, oligodendrogliomas, and meningiomas. The 
Ki-67 LI was found to be increased in oligoastrocytomas 
and anaplastic astrocytomas than the well differentiated 
oligodendrogliomas (26 and present study). However, the 
Ag-NOR value we obtained in the oligodendroglial tumors 
did not correlate with the histologic grades. Morever, we 
did not find any correlation between the more reliable 
tumor marker Ki-67 with the Ag-NOR number in the same 
tumor samples. Although there is some relationship 
between NORs and the cell cycle'", the number of Ag-NORs 
may not measure the cellular proliferation activity di-
rectly. 
 In conclusion, the present study suggests that the 
assessment of the tumor Ki-67 Labeling index is useful 
criteria to distinguish between benign and malignant 
brain tumors, and may influence the treatment of choice 
and outcome of patients.
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